AstraZeneca’s immunotherapy, Imfinzi, arrived to the industry as a failure – there were big hopes resting on the company’s Mystic trial, with the potential to leapfrog other treatments on the market with a successfully combination treatment.
Of course, in one of the biggest stories of last year, it did not succeed and instead wiped $10 billion from the company’s value.
